{"disease":{"id":"nf1","name":"nf1"},"drugs":{"marketed":[{"drug_id":"selumetinib","indication_name":"Treatment of adult and pediatric patients 1 year of age and older with neurofibromatosis type 1 (NF1) who have symptomatic, inoperable plexiform neurofibromas (PN)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Koselugo","generic_name":"selumetinib","company_name":"ASTRAZENECA LP","drug_phase":"marketed","molecular_target":"AP2-associated protein kinase 1","drug_class":"Kinase Inhibitor [EPC]","quality_score":75,"revenue":null,"mechanism":"Selumetinib is an inhibitor of mitogen-activated protein kinase kinases 1 and 2 (MEK1/2)."},{"drug_id":"selumetinib","indication_name":"Treatment of adult and pediatric patients 1 year of age and older with neurofibromatosis type 1 (NF1)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Koselugo","generic_name":"selumetinib","company_name":"ASTRAZENECA LP","drug_phase":"marketed","molecular_target":"AP2-associated protein kinase 1","drug_class":"Kinase Inhibitor [EPC]","quality_score":75,"revenue":null,"mechanism":"Selumetinib is an inhibitor of mitogen-activated protein kinase kinases 1 and 2 (MEK1/2)."}],"pipeline":[],"offLabel":[],"totalMarketed":2,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT07327164","title":"Precision Medicine for Neurocutaneous Syndromes in Western China","phase":"","overall_status":"COMPLETED","enrollment_count":1200,"lead_sponsor_name":"West China Hospital","has_results":false},{"nct_id":"NCT00684398","title":"Adaptation and Quality of Life Among Adults With Neurofibromatosis Type I","phase":"","overall_status":"COMPLETED","enrollment_count":645,"lead_sponsor_name":"National Human Genome Research Institute (NHGRI)","has_results":false},{"nct_id":"NCT01702922","title":"Relationship Stressors in Parents of Children With Cancer or Neurofibromatosis Type 1 (NF1)","phase":"","overall_status":"COMPLETED","enrollment_count":262,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT05913037","title":"FCN-159 in Adult Patients With Symptomatic, Inoperable Neurofibromatosis Type 1-Related Plexiform Neurofibromas","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":167,"lead_sponsor_name":"Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.","has_results":false},{"nct_id":"NCT04954001","title":"Study to Evaluate the Safety, Tolerability, PK Characteristics and Anti-tumor Activity of FCN-159 in Adult and Pediatric Participants With Neurofibromatosis Type 1","phase":"PHASE1, PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":160,"lead_sponsor_name":"Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.","has_results":false},{"nct_id":"NCT03962543","title":"MEK Inhibitor Mirdametinib (PD-0325901) in Patients With Neurofibromatosis Type 1 Associated Plexiform Neurofibromas","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":114,"lead_sponsor_name":"SpringWorks Therapeutics, Inc.","has_results":true},{"nct_id":"NCT01362803","title":"AZD6244 Hydrogen Sulfate for Children With Nervous System Tumors","phase":"PHASE1, PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":99,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT05735717","title":"MT2021-08T Cell Receptor Alpha/Beta Depletion PBSC Transplantation for Heme Malignancies","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":70,"lead_sponsor_name":"Masonic Cancer Center, University of Minnesota","has_results":false},{"nct_id":"NCT07024394","title":"Follow-up Study to Evaluate the Safety and Efficacy of FCN-159 in Pediatric Participants With Neurofibromatosis Type 1","phase":"PHASE1, PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":65,"lead_sponsor_name":"Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.","has_results":false},{"nct_id":"NCT07521657","title":"Efficacy of Mirdametinib Alone or Combination With Radiotherapy for Germline and Sporadic NF1-Altered High-Grade Glioma","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":55,"lead_sponsor_name":"University of Alabama at Birmingham","has_results":false},{"nct_id":"NCT03872427","title":"Testing Whether Cancers With Specific Mutations Respond Better to Glutaminase Inhibitor, Telaglenastat Hydrochloride, Anti-Cancer Treatment, BeGIN Study","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":54,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT06735820","title":"Early Phase Study Evaluating MEK and MDM2 Inhibition in Patients With NF1 and MPNST","phase":"PHASE1, PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":45,"lead_sponsor_name":"AeRang Kim","has_results":false},{"nct_id":"NCT05253131","title":"Trial of Selumetinib and Bromodomain Inhibitor With Durvalumab for Sarcomas","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":41,"lead_sponsor_name":"University of Alabama at Birmingham","has_results":false},{"nct_id":"NCT02407405","title":"MEK 1/2 Inhibitor Selumetinib (AZD6244 Hydrogen Sulfate) in Adults With Neurofibromatosis Type 1 (NF1) and Inoperable Plexiform Neurofibromas","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":36,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT03672838","title":"A Single Center Pilot Study to Assess the Intra-observer Reliability of Measuring Muscle Strength Using a Hand Held Dynamometer in Children and Adults With Neurofibromatosis Type 1 (NF1) and Type 2 (NF2)","phase":"NA","overall_status":"COMPLETED","enrollment_count":33,"lead_sponsor_name":"NYU Langone Health","has_results":false},{"nct_id":"NCT06287463","title":"Study of DCC-3084 in Participants With Advanced Malignancies Driven by the Mitogen-Activated Protein Kinase (MAPK) Pathway","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":29,"lead_sponsor_name":"Deciphera Pharmaceuticals, LLC","has_results":false},{"nct_id":"NCT01968590","title":"Vitamin D Supplementation for Adults With Neurofibromatosis Type 1 (NF1)","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":26,"lead_sponsor_name":"University of Utah","has_results":false},{"nct_id":"NCT03649165","title":"A Study to Evaluate Bioavailability and Food Effect of Selumetinib (AZD6244) in Healthy Male Participants","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":24,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT00006435","title":"Study of Plexiform Neurofibromas in Neurofibromatosis Type 1","phase":"","overall_status":"COMPLETED","enrollment_count":24,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT06159166","title":"Mirdametinib Monotherapy in Adults With Neurofibromatosis 1 (NF1) and Cutaneous Neurofibromas (cNF).","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":24,"lead_sponsor_name":"Johns Hopkins University","has_results":false},{"nct_id":"NCT06104488","title":"A Study of Avutometinib for People With Solid Tumor Cancers","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":23,"lead_sponsor_name":"Memorial Sloan Kettering Cancer Center","has_results":false},{"nct_id":"NCT05831995","title":"Safety and Effectiveness of ABM-168 in Adults with Advanced Solid Tumors.","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":12,"lead_sponsor_name":"ABM Therapeutics Corporation","has_results":false},{"nct_id":"NCT02718131","title":"A Study of INFUSE Bone Graft (BMP-2) in the Treatment of Tibial Pseudarthrosis in Neurofibromatosis Type 1 (NF1)","phase":"NA","overall_status":"TERMINATED","enrollment_count":5,"lead_sponsor_name":"University of Alabama at Birmingham","has_results":true},{"nct_id":"NCT04544007","title":"A Phase II Trial of Poly-ICLC for Low-Grade Gliomas","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":3,"lead_sponsor_name":"University of Alabama at Birmingham","has_results":true}],"total":24},"guidelines":[],"source":"Drug Landscape verified database"}